MARKET

MYMD

MYMD

Mymd Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.490
+0.150
+6.41%
Closed 16:00 07/05 EDT
OPEN
2.290
PREV CLOSE
2.340
HIGH
2.505
LOW
2.240
VOLUME
39.98K
TURNOVER
71.61K
52 WEEK HIGH
9.95
52 WEEK LOW
1.880
MARKET CAP
94.77M
P/E (TTM)
-2.9544
1D
5D
1M
3M
1Y
5Y
BRIEF-Mymd Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial Of Mymd-1
reuters.com · 06/21 17:57
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 As Therapy For Delaying Aging And Extending Healthy Lifespan
MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further advancement in
Benzinga · 06/21 14:31
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan
BALTIMORE, June 21, 2022--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further advancement in its fully-funded, multi-center Phase 2 c...
Business Wire · 06/21 14:30
MyMD Pharmaceuticals Says Patient Enrollment Under Way at All Sites in Phase 2 Study of Therapy to Delay Aging
MT Newswires · 06/21 12:37
BRIEF-MyMD Pharma's Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in Preclinical Model
reuters.com · 04/12 13:33
MyMD Pharmaceuticals, Inc. Announces Preclinical Study Data On MYMD-1 Showing 'significantly greater anti-inflammatory effect than current TNF-alpha inhibitors on the market'
MyMD seeks to disrupt the $31 billion global market for rheumatoid arthritis (RA) drug therapies with MYMD-1, which could potentially prove safer, more effective and better tolerated than current
Benzinga · 04/12 13:32
MyMD Says Preclinical Data Show 'Greater Anti-Inflammatory Effect' of Rheumatoid Arthritis Drug Over Top-Selling Therapies
MT Newswires · 04/12 10:50
MyMD Pharmaceuticals Accelerates Pace Of New Patient Dosing In Phase 2 Clinical Trial Of MYMD-1 As A Therapy For Delaying Aging And Extending Healthy Lifespan
MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) ("MyMD" or "the Company"), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced an acceleration in the pace of
Benzinga · 04/05 13:22
More
No Data
Learn about the latest financial forecast of MYMD. Analyze the recent business situations of Mymd Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MYMD stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
High4.000
Average4.000
Low4.000
Current 2.490
EPS
Actual
Estimate
-0.40-0.30-0.20-0.10
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 45
Institutional Holdings: 5.01M
% Owned: 13.15%
Shares Outstanding: 38.06M
TypeInstitutionsShares
Increased
6
644.34K
New
3
37.46K
Decreased
14
105.58K
Sold Out
9
151.77K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.07%
Pharmaceuticals & Medical Research
+0.40%
Key Executives
Chairman/Lead Director/Independent Director
Joshua Silverman
President/Director
Chris Chapman
Chief Financial Officer
Ian Rhodes
Executive Vice President/General Counsel
Paul Rivard
Chief Scientific Officer
Adam Kaplin
Director
Craig Eagle
Director
Jude Uzonwanne
Independent Director
Bill White
No Data
No Data
About MYMD
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MYMD-1 is a clinical-stage small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MYMD-1 is being developed to treat age-related illnesses, such as frailty and sarcopenia. MYMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-a, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic analog of cannabidiol (CBD) being developed to treat various conditions, including epilepsy, pain and anxiety/depression, through its effects on the CB2 receptor, opioid receptors and monoamine oxidase enzyme (MAO) type B. Supera-CBD is also used in treating neuroinflammatory and neurodegenerative diseases.

Webull offers kinds of MyMD Pharmaceuticals Inc stock information, including NASDAQ:MYMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MYMD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MYMD stock methods without spending real money on the virtual paper trading platform.